Rapid eConsent Implementation Contributes to DCT Advancement in Japan

In a groundbreaking study for Major Depressive Disorder (MDD), a major Japanese pharmaceutical company partnered with Signant to implement a decentralized clinical trial (DCT) model using SmartSignals eConsent.

 

This innovative approach helped address common barriers to trial participation, including time and physical constraints, by enabling remote informed consent and central rating COA measurement.

 

The results? Faster patient enrollment, improved engagement, and a smoother trial experience for patients and sites alike.

The approach also helped validate the use of decentralized methodologiesin Japanese clinical research. 

 

Discover how Signant’s eConsent solution facilitated rapid enrollment, enhanced participation, and improved data quality in this validation phase study.